Combined Therapy With Adipose-Derived Mesenchymal Stem Cells and Ciprofloxacin Against Acute Urogenital Organ Damage in Rat Sepsis Syndrome Induced by Intrapelvic Injection of Cecal Bacteria

Sung, Pei‐Hsun; Chiang, Hsin‐Ju; Chen, Chih‐Hung; Huang, Tung‐Liang; Zhen, Yen-Yi; Chang, Meng-Wei; Liu, Chu-Feng; Chung, Sheng-Ying; Chen, Yung‐Lung; Chai, Han‐Tan; Sun, Cheuk‐Kwan; Yip, Hon‐Kan

doi:10.5966/sctm.2015-0116

Cited by 33 publications

(40 citation statements)

References 28 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSC therapy has reduced rodent mortality in SS [ 32 ], and both autologous and allogenic ADMSC have the capacity of immune privilege [ 16 , 29 , 31 – 33 ]. The present study showed that in animals with ARDS-SS, early administration of xenogeneic MSC reduces the mortality rate compared to no treatment.…”

Section: Discussionmentioning

confidence: 99%

“…The procedure and protocol for Western blot analysis were based on our recent reports [ 32 , 35 , 37 ]. Briefly, equal amounts (50 μg) of protein extracts were loaded and separated by SDS-PAGE using acrylamide gradients.…”

Section: Methodsmentioning

confidence: 99%

“…IF staining has been described in our previous reports [ 32 , 35 , 37 ]. For IHC and IF staining, rehydrated paraffin sections were first treated with 3% H 2 O 2 for 30 minutes and incubated with Immuno-Block reagent (BioSB, Santa Barbara, CA, USA) for 30 minutes at room temperature.…”

Section: Methodsmentioning

confidence: 99%

“…Histopathology scoring was assessed in a blinded fashion as we have previously described [ 32 , 35 , 37 ]. The scoring system reflecting the grading of tubular necrosis, loss of brush border, cast formation, and tubular dilatation in 10 randomly chosen, non-overlapping fields (200x) was as follows: 0 (none), 1 (≤10%), 2 (11–25%), 3 (26–45%), 4 (46–75%), and 5 (≥76%).…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Xenogeneic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis

et al. 2017

Self Cite

View full text Add to dashboard Cite

This study tested the hypothesis that xenogeneic human umbilical cord-derived mesenchymal stem cell (HUCDMSC) therapy would improve survival rates in rats with acute respiratory distress-syndrome (ARDS, induction by 48 h inhalation of 100% oxygen) and sepsis-syndrome (SS, induction by cecal-ligation and puncture) (ARDS-SS). Adult-male Sprague-Dawley rats were categorized into group 1 (sham-controls), group 2 (ARDS-SS), group 3 [ARDS-SS+HUCDMSC (1.2 ×106 cells administered 1 h after SS-induction)], and group 4 [ARDS-SS+HUCDMSC (1.2 ×106 cells administered 24 h after SS-induction)]. The mortality rate was higher in groups 2 and 4 than in groups 1 and 3 (all p<0.0001). The blood pressure after 28 h was lower in groups 2, 3 and 4 (p<0.0001) than in group 1. Albumin levels and percentages of inflammatory cells in broncho-alveolar lavage fluid, and the percentages of inflammatory and immune cells in circulation, were lowest in group 1, highest in group 2, and higher in group 3 than group 4 (all p<0.0001). The percentages of inflammatory cells in ascites and kidney parenchyma showed identical patterns, as did kidney injury scores (all p<0.0001). EarlyHUCDMSC therapy reduced rodent mortality after induced ARDS-SS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Xenogeneic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…To achieve improved fat-graft survival, ADSC based-tissue engineering and regeneration are recently co-introduced in the surgical fields where autologous fat grafts alone have been in charge [3456]. Recent studies have also investigated whether stem cell therapy with ADSCs can be used for improving the outcome of patients in intensive care units, including the acute urogenital organ damage observed in sepsis [7] and toxic shock syndrome [8]. Several factors should be considered to achieve successful stem cell therapy [9].…”

Section: Introductionmentioning

confidence: 99%

The effects of etomidate and midazolam on adipose tissue-derived mesenchymal stem cell proliferation

Park

Ryu

Kim

et al. 2016

Korean J Anesthesiol

View full text Add to dashboard Cite

BackgroundStem cell therapy using adipose tissue-derived mesenchymal stem cells (ADSCs), which are capable of multipotent differentiation, is currently being investigated in the field of tissue regeneration and the treatment of patients in intensive care units. It is known that type-A γ-aminobutyric acid (GABAA) receptor activity has an influence on stem cell proliferation. Thus, we investigated the effects of the clinically available GABAA receptor agonists, etomidate and midazolam, on ADSC proliferation measured by the cell counting kit-8 assay.MethodsADSCs cultured in control medium or adipogenic differentiation medium for 15 days were divided into 5 treatment groups: non-medicated (Control) and 4 groups including treatment with etomidate or midazolam at 1 and 50 µM (n = 3 per group). The cell counting kit-8 assay was performed for determining the cell proliferation in both medium groups at day 0, 3, 6, 9, 12, and 15 in culture. The absorbance values at 450 nm were then measured by enzyme-linked immunosorbent assay reader and statistically compared among groups.ResultsThere was no significant difference in cell proliferation profiles among the 5 groups at any time point in both control and adipogenic differentiation media.ConclusionsEtomidate and midazolam did not influence ADSC proliferation under both media when compared to the non-medicated group and there was no dose-dependent effect of etomidate and midazolam on ADSC viability.

show abstract

Concise Review: Mesenchymal Stromal Cell-Based Approaches for the Treatment of Acute Respiratory Distress and Sepsis Syndromes

Johnson

Soeder

Dahlke

2017

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Despite extensive research on candidate pharmacological treatments and a significant and increasing prevalence, sepsis syndrome, and acute respiratory distress syndrome (ARDS) remain areas of unmet clinical need. Preclinical studies examining mesenchymal stromal cell (MSCs) based‐therapies have provided compelling evidence of potential benefit; however, the precise mechanism by which MSCs exert a therapeutic influence, and whether MSC application is efficacious in humans, remains unknown. Detailed evaluation of the limited number of human trials so far completed is further hampered as a result of variations in trial design and biomarker selection. This review provides a concise summary of current preclinical and clinical knowledge of MSCs as a cell therapy for sepsis syndrome and ARDS. The challenges of modeling such heterogeneous and rapidly progressive disease states are considered and we discuss how lessons from previous studies of pharmacological treatments for sepsis syndrome and ARDS might be used to inform and refine the design of the next generation of MSC clinical trials. Stem Cells Translational Medicine 2017;6:1141–1151

show abstract

Combined Therapy With Adipose-Derived Mesenchymal Stem Cells and Ciprofloxacin Against Acute Urogenital Organ Damage in Rat Sepsis Syndrome Induced by Intrapelvic Injection of Cecal Bacteria

Abstract: Combined therapy with autologous adipose‐derived mesenchymal stem cells and ciprofloxacin was found to be superior to either therapy alone in improving the outcome in a rodent sepsis model.

Cited by 33 publications

References 28 publications

Xenogeneic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis

Xenogeneic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis

The effects of etomidate and midazolam on adipose tissue-derived mesenchymal stem cell proliferation

Concise Review: Mesenchymal Stromal Cell-Based Approaches for the Treatment of Acute Respiratory Distress and Sepsis Syndromes

Contact Info

Product

Resources

About